We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current STX market cap is 12.41M. The company's latest EPS is GBP -0.0429 and P/E is -0.37.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Total Revenue | 719k | 10.39M | 1.52M | 5.5M | 13.09M |
| Operating Income | -9.04M | -2.15M | -20.29M | -49.75M | -31.33M |
| Net Income | -8.8M | -2.63M | -19.68M | -49.79M | -33.29M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Total Assets | 36.32M | 32.53M | 44.41M | 26.62M | 48.8M |
| Total Liabilities | 4.17M | 2.25M | 3.72M | 20.07M | 33.77M |
| Total Equity | 32.15M | 30.28M | 40.69M | 6.54M | 15.03M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Operating | -4.07M | -1.4M | -18.26M | -22.59M | -37.13M |
| Investing | -1.37M | -20k | -2.05M | -2.25M | -2.43M |
| Financing | -203k | -47k | 27.71M | 8.53M | 49.66M |
| Market Cap | 12.41M |
| Price to Earnings Ratio | -0.37 |
| Price to Sales Ratio | 0.95 |
| Price to Cash Ratio | 0.89 |
| Price to Book Ratio | 0.83 |
| Dividend Yield | - |
| Shares Outstanding | 775.43M |
| Average Volume (1 week) | 981.77k |
| Average Volume (1 Month) | 1.21M |
| 52 Week Change | -75.76% |
| 52 Week High | 12.75 |
| 52 Week Low | 1.075 |
| Spread (Intraday) | 0.1 (6.06%) |
| Company Name | Shield Therapeutics Plc |
| Address |
northern design centre newcastle upon tyne NE8 3DF |
| Website | https://www.shieldtherapeutics.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
